[1]
Fagge CH. Xanthomatous disease of the skin. I. General xanthelasma or vitiligoides. Trans Pathol Soc Lond 1873; 24: 242-50.
[2]
Goldstein JL, Dana SE, Brown MS. Esterification of low density lipoprotein cholesterol in human fibroblasts and its absence in homozygous familial hypercholesterolemia. Proc Natl Acad Sci USA 1974; 71: 4288-92.
[3]
Lindgren V, Luskey KL, Russell DW, Francke U. Human genes involved in cholesterol metabolism: Chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. Proc Natl Acad Sci USA 1985; 82: 8567-71.
[4]
Leigh S, Futema M, Whittall R, et al. The UCL low-density lipoprotein receptor gene variant database: Pathogenicity update. J Med Genet 2017; 54: 217-23.
[5]
Benn M, Watts GF, Tybaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97: 3956-64.
[6]
Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016; 67: 2578-89.
[7]
Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: A model of care for Australasia. Atheroscler Suppl 2011; 12: 221-63.
[8]
Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36: 2425-37.
[9]
Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 2011; 5: 1-8.
[10]
Primary Panel: Genest J, Hegele RA, Bergeron J, et al. Canadian cardiovascular society position statement on familial hypercholesterolemia. Can J Cardiol 2014; 30: 1471-81.
[11]
Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223: 262-8.
[12]
Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171: 309-25.
[13]
Ellis KL, Pang J, Watts GF. Registries, codifications and cardiovascular outcomes in familial hypercholesterolaemia. Eur J Prev Cardiol 2017; 24: 133-6.
[14]
Mundal L, Retterstol K. A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries. Curr Opin Lipidol 2016; 27: 388-97.
[15]
Kindt I, Mata P, Knowles JW. The role of registries and genetic databases in familial hypercholesterolemia. Curr Opin Lipidol 2017; 28: 152-60.
[16]
Thompson GR, Blom DJ, Marais AD, et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J 2018; 39: 1162-8.
[17]
Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011; 124: 2202-7.
[18]
Bruckert E, Kalmykova O, Bittar R, et al. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis 2017; 257: 130-7.
[19]
Bellgard MI, Walker CE, Napier KR, et al. Design of the familial hypercholesterolaemia australasia network registry: Creating opportunities for greater international collaboration. J Atheroscler Thromb 2017; 24: 1075-84.
[20]
Pérez-Calahorra S, Sánchez-Hernández RM, Plana N, Valdivielso P, Civeira F. National dyslipidemia registry of the spanish arteriosclerosis society: Current status. Clin Investig Arterioscler 2017; 29: 248-53.
[21]
Schmidt N, Grammer T, Gouni-Berthold I, et al. Care high - Cascade screening and registry for high cholesterol in Germany. Atheroscler Suppl 2017; 30: 72-6.
[22]
Arnold-Reed DE, Brett T, Troeung L, et al. Detection and management of familial hypercholesterolaemia in primary care in Australia: Protocol for a pragmatic cluster intervention study with pre-post intervention comparisons. BMJ Open 2017; 7e017539
[23]
Kayikçioğlu M, Tokgözoğlu L. The rationale and design of the national familial hypercholesterolemia registries in Turkey: A-HIT1 and A-HIT2 studies. Turk Kardiyol Dern Ars 2017; 45: 261-7.
[24]
Al-Rasadi K, Alhabib KF, Al-Allaf F, et al. The Gulf familial hypercholesterolemia registry (Gulf FH): Design, rationale and preliminary results. Curr Vasc Pharmacol 2020; 18(1): 57-64.
[25]
El-Hazmi MA, al-Swailem AR, Warsy AS, et al. Consanguinity among the Saudi Arabian population. J Med Genet 1995; 32: 623-6.
[26]
Al-Rasadi K, Al-Zakwani I, Alsheikh-Ali AA, et al. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol 2018; 12: 685-92.
[27]
Bamimore MA, Zaid A, Banerjee Y, et al. Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry. J Clin Lipidol 2015; 9: 187-94.
Call for Papers in Thematic Issues
31 January, 2025
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
Related Journals
Current Drug Safety
Current Cardiology Reviews
Cardiovascular & Hematological Agents in Medicinal Chemistry
Current Hypertension Reviews
Cardiovascular & Hematological Disorders-Drug Targets
Current Neuropharmacology
Current Pharmaceutical Design
Current Pharmaceutical Analysis
CNS & Neurological Disorders - Drug Targets
Current Molecular Pharmacology
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Herbal Medicine: Back to the Future
Cardiac Care and COVID-19: Perspectives in Medical Practice
Nanomedicinal Approaches Towards Cardiovascular Disease
Postbiotics: Science, Technology and Applications
Article Metrics
34
3